Prognostic Utility Of Novel Biomarkers in Aortic Valve Stenosis
By:
References
- Akahori, H., Tsujino, T., Masuyama, T., Ishihara, M. (2018). Mechanisms of aortic stenosis.
J. Cardiol .,71 (3), 215–220. - Ali, O. A., Chapman, M., Nguyen, T. H., Chirkov, Y. Y., Heresztyn, T., Mundisugih, J., Horowitz, J. D. (2014). Interactions between inflammatory activation and endothelial dysfunction selectively modulate valve disease progression in patients with bicuspid aortic valve.
Heart ,100 (10), 800–805. - Chen, B., Meng, L., Shen, T., Gong, H., Qi, R., Zhao, Y., Sun, J., Bao, L., Zhao, G. (2017). Thioredoxin attenuates oxidized low-density lipoprotein induced oxidative stress in human umbilical vein endothelial cells by reducing NADPH oxidase activity.
Biochem. Biophys. Res. Commun .,490 (4), 1326–1333. - Cheng, P., Zhang, F., Yu, L., Lin, X., He, L., Li, X., Lu, X., Yan, X., Tan, Y., Zhang, C. (2016). Physiological and pharmacological roles of FGF21 in cardiovascular diseases.
J. Diabetes Res .,2016 , 1540267. - Couchie, D., Vaisman, B., Abderrazak, A., Mahmood, D. F. D., Hamza, M. M., Canesi, F., Diderot, V., El Hadri, K., Nègre-Salvayre, A., Le Page, A., Fulop, T., Remaley, A. T., Rouis, M. (2017). Human plasma thioredoxin-80 increases with age and in ApoE-/-mice induces inflammation, angiogenesis, and atherosclerosis.
Circulation ,136 (5), 464–475. - El Hadri, K., Mahmood, D. F., Couchie, D., Jguirim-Souissi, I., Genze, F., Diderot, V., Syrovets, T., Lunov, O., Simmet, T., Rouis, M. (2012). Thioredoxin-1 promotes anti-inflammatory macrophages of the M2 phenotype and antagonizes atherosclerosis.
Arterioscler. Thromb. Vasc. Biol. ,32 (6), 1445–1452. - Fondard, O., Detaint, D., Iung, B., Choqueux, C., Adle-Biassette, H., Jarraya, M., Hvass, U., Couetil, J. P., Henin, D., Michel, J. B., Vahanian, A., Jacob, M. P. (2005). Extracellular matrix remodelling in human aortic valve disease: the role of matrix metalloproteinases and their tissue inhibitors.
Eur. Heart J .,26 (13), 1333–1341. - Heymans, S., Schroen, B., Vermeersch, P., Milting, H., Gao, F., Kassner, A., Gillijns, H., Herijgers, P., Flameng, W., Carmeliet, P., Van de Werf, F., Pinto, Y. M., Janssens, S. (2005). Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart.
Circulation ,112 (8), 1136–1144. - Ji, Q., Lin, Y., Liang, Z., Yu, K., Liu, Y., Fang, Z., Liu, L., Shi, Y., Zeng, Q., Chang, C., Chai, M., Zhou, Y. (2014). Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris.
Cardiovasc. Diabetol .,13 , 145. - Kammerer, A., Staab, H., Herberg, M., Kerner, C., Klöting, N., Aust, G. (2018). Increased circulating chemerin in patients with advanced carotid stenosis. BMC
Cardiovasc. Disord .,18 (1), 65. - Kaur, J. L., Mattu, H. S., Chatha, K., Randeva, H. S. (2018). Chemerin in human cardiovascular disease.
Vascul. Pharmacol .,110 , 1–6. - Khan, A. A., Alsahli, M. A., Rahmani, A. H. (2018). Myeloperoxidase as an active disease biomarker: Recent biochemical and pathological perspectives.
Med. Sci. (Basel) ,6 (2). pii: E33. - Kim, J. B., Kobayashi, Y., Kuznetsova, T., Moneghetti, K. J., Brenner, D. A., O’Malley, R., Dao, C., Wu, J. C., Fischbein, M., Craig Miller, D., Yeung, A. C., Liang, D., Haddad, F., Fearon, W. F. (2018).
Int. J. Cardiol .,270 , 83–88. - Kunimoto, H., Kazama, K., Takai, M., Oda, M., Okada, M., Yamawaki, H. (2015). Chemerin promotes the proliferation and migration of vascular smooth muscle and increases mouse blood pressure.
Amer. J. Physiol. Heart Circ. Physiol .,309 (5), H1017–H1028. - Lenart-Lipińska, M., Duma, D., Hałabiś, M., Dziedzic, M., Solski, J. (2016). Fibroblast growth factor 21 — a key player in cardiovascular disorders?
Horm. Mol. Biol. Clin. Investig. ,30 (2). - Lurins, J., Lurina, D., Tretjakovs, P., Mackevics,V., Lejnieks, A., Rapisarda, V., Baylon, V. (2018). Increased serum chemerin level to predict early onset of aortic valve stenosis.
Biomed. Rep .,8 (1), 31–36. - Münch, J., Avanesov, M., Bannas, P., Säring, D., Krämer, E., Mearini, G., Carrier, L., Suling, A., Lund, G., Patten, M. (2016). Serum matrix metalloproteinases as quantitative biomarkers for myocardial fibrosis and sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy.
J. Card. Fail .,22 (10), 845–850. - Nussbaum, C., Klinke, A., Adam, M., Baldus, S., Sperandio, M. (2013). Myeloperoxidase: A leukocyte-derived protagonist of inflammation and cardiovascular disease.
Antioxid. Redox Signal ,18 (6), 692–713. - Perrotta, I., Sciangula, A., Aquila, S., Mazzulla, S. (2016). Matrix metalloproteinase-9 expression in calcified human aortic valves: A histopathologic, immunohistochemical, and ultrastructural study.
Appl. Immunohistochem. Mol. Morphol. ,24 (2), 128–137. - Planavila, A., Redondo-Angulo, I., Ribas, F., Garrabou, G., Casademont, J., Giralt, M., Villarroya, F. (2015a). Fibroblast growth factor 21 protects the heart from oxidative stress.
Cardiovasc. Res .,106 (1), 19–31. - Planavila, A., Redondo-Angulo, I., Villarroya, F. (2015b). FGF21 and cardiac physiopathology.
Front. Endocrinol. (Lausanne) ,6 , 133. - Savic-Radojevic, A., Pljesa-Ercegovac, M., Matic, M., Simic, D., Radovanovic, S., Simic, T. (2017). Novel biomarkers of heart failure.
Adv. Clin. Chem .,79 , 93–152. - Spiroglou, S. G., Kostopoulos, C. G., Varakis, J. N., Papadaki, H. H. (2010). Adipokines in periaortic and epicardial adipose tissue: Differential expression and relation to atherosclerosis.
J. Atheroscler. Thromb .,17 (2), 115–130. - Stein, J. H, Korcarz, C. E., Hurst, R. T., Lonn, E., Kendall, C. B., Mohler, E. R., Najjar, S. S., Rembold, C. M., Post, W. S.; American Society of Echocardiography Carotid Intima-Media Thickness Task Force (2008). Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force.
J. Amer. Soc. Echocardiogr .,21 , 93–111. - Vahanian, A., Iung, B. (2012). The new ESC/EACTS guidelines on the management of valvular heart disease.
Arch. Cardiovasc. Dis .,105 , 465–467. - van der Veen, B. S., de Winther, M. P., Heeringa, P. (2009). Myeloperoxidase: Molecular mechanisms of action and their relevance to human health and disease.
Antioxid. Redox Signal ,11 (11), 2899–2937. - Wada, S., Sugioka, K., Naruko, T., Kato, Y., Shibata, T., Inoue, T., Inaba, M., Ohsawa, M., Yoshiyama, M., Ueda, M. (2013). Myeloperoxidase and progression of aortic valve stenosis in patients undergoing hemodialysis.
J. Heart Valve Dis .,22 (5), 640–647. - Yamawaki, H., Kameshima, S., Usui, T., Okada, M., Hara. Y. (2012). A novel adipocytokine, chemerin exerts anti-inflammatory roles in human vascular endothelial cells.
Biochem. Biophys. Res. Commun .,423 (1), 152–157. - Yao, Q., Song, R., Ao, L., Cleveland, J. C Jr., Fullerton, D. A., Meng, X. (2017). Neurotrophin 3 upregulates proliferation and collagen production in human aortic valve interstitial cells: a potential role in aortic valve sclerosis.
Amer. J. Physiol. Cell Physiol .,312 (6), C697–C706. - Zhang, H., Liu, Q., Lin, J. L., Wang, Y., Zhang, R. X., Hou, J. B., Yu, B. (2018). Recombinant human thioredoxin-1 protects macrophages from oxidized low-density lipoprotein-induced foam cell formation and cell apoptosis.
Biomol. Ther. (Seoul), 26 (2), 121–129.
Language: English
Page range: 100 - 106
Submitted on: Nov 5, 2018
Accepted on: Jan 3, 2019
Published on: Apr 7, 2019
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 times per year
Keywords:
Related subjects:
© 2019 Pēteris Tretjakovs, Juris Hofmanis, Dace Hofmane, Gita Krieviņa, Leons Blumfelds, Vitolds Mackēvičs, Aivars Lejnieks, Guntis Bahs, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.